iDNA Genomics Public (CYS:IDNA) EBIT per Share: € (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €22.80
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public EBIT per Share?

iDNA Genomics Public CYS:IDNA 23 EBIT per Share is € as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

iDNA Genomics Public's EBIT per Share for the six months ended in . 20 was €0.00. iDNA Genomics Public does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for iDNA Genomics Public's EBIT per Share or its related term are showing as below:

CYS:IDNA's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

iDNA Genomics Public's EBIT for the six months ended in . 20 was €0.00 Mil.

iDNA Genomics Public  (CYS:IDNA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

iDNA Genomics Public EBIT per Share Related Terms

iDNA Genomics Public EBIT per Share Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public EBIT per Share Chart

iDNA Genomics Public Annual Data
Trend
EBIT per Share

iDNA Genomics Public Semi-Annual Data
EBIT per Share
CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

iDNA Genomics Public's EBIT per Share for the fiscal year that ended in . 20 is calculated as

EBIT per Share(A: . 20 )
=EBIT/Shares Outstanding (Diluted Average)
=/0
=N/A

iDNA Genomics Public's EBIT per Share for the quarter that ended in . 20 is calculated as

EBIT per Share(Q: . 20 )
=EBIT/Shares Outstanding (Diluted Average)
=/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of € mean?
iDNA Genomics Public (CYS:IDNA) has a EBIT per Share of € as of . 20. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on iDNA Genomics Public and its competitors.
Is iDNA Genomics Public's EBIT per Share too high?
iDNA Genomics Public's current EBIT per Share is €. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's EBIT per Share compare to ?
iDNA Genomics Public's EBIT per Share of € can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on iDNA Genomics Public and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iDNA Genomics Public's current EBIT per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current EBIT per Share of €. The current EBIT per Share is €. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current EBIT per Share is € as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price